(Q36585280)

15 August 2017

1 reference

title

The evolving role of leptin and adiponectin in chronic liver diseases (English)

1 reference

15 August 2017

main subject

chronic liver disease

0 references

author

Emmanuel Tsochatzis

series ordinal

1

1 reference

15 August 2017

author name string

George V Papatheodoridis

series ordinal

2

1 reference

15 August 2017

Athanasios J Archimandritis

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

4 September 2006

1 reference

The American Journal of Gastroenterology

15 August 2017

published in

1 reference

15 August 2017

volume

101

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

2629-2640

1 reference

Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatosis: co-factor in other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Hepatic steatosis: innocent bystander or guilty party?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin and its receptors in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Abnormal splicing of the leptin receptor in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin Regulates Functional Capacities of Polymorphonuclear Neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin: cutting the fat off the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin is a growth factor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

The role of the novel adipocyte-derived hormone adiponectin in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin and development of type 2 diabetes in the Pima Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Modulation of insulin activities by leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

NASH: a mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin is essential for the hepatic fibrogenic response to chronic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Adiponectin and its receptors in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Steatosis affects chronic hepatitis C progression in a genotype specific way

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Diabetes mellitus and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Fibrogenic impact of high serum glucose in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Serum adiponectin concentration in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Serum leptin levels in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00848.X

10.1111/J.1572-0241.2006.00848.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference